On-Demand Webinar: Orphan Drug Designation - The Considerations, The Rewards, and How They Differ Between The US and Europe
Learn about Orphan Drug Designation (ODD) - the considerations, rewards, and how they differ between the US and Europe.
1 min read
Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or condition should consider applying for the Orphan Drug Designation (ODD) program with the FDA. The FDA’s Orphan Drug Designation program is meant to encourage the development of therapies for rare diseases and provides incentives for orphan products including exemption from user fees, a potential for 7 years of market exclusivity, and tax credits for some clinical trials.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about Orphan Drug Designation classification and the strategic use of orphan subsets in study design.
Learning Points
- Orphan Drug Designation criteria
- What makes a subgroup of a disease ‘inappropriate’ or ‘scientifically justified’ for orphan drug designation?
- Scenario examples of how to determine a ‘scientifically justified' orphan subgroup.
Meet Veristat. Learn More.
Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)
Cindy Henderson, Chief Commercial Officer : January 9, 2023
Takeaways from the Tufts Center for the Study of Drug Development (CSDD) Roundtable, Quantifying the Value Proposition of DCT Deployments, Boston, MA
The Evolving Landscape of Radiopharmaceuticals in Oncology Research
Radiopharmaceuticals have been around for decades, but their role in oncology is expanding rapidly. With the increasing focus on targeted therapies,...